149 related articles for article (PubMed ID: 33246030)
21. Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas.
Song W; Qian L; Jing G; Jie F; Xiaosong S; Chunhui L; Yangfang L; Guilin L; Gao H; Yazhuo Z
Mol Cell Endocrinol; 2018 Oct; 474():168-175. PubMed ID: 29555596
[TBL] [Abstract][Full Text] [Related]
22. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
[TBL] [Abstract][Full Text] [Related]
23. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
24. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
25. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Meador CB; Jin H; de Stanchina E; Nebhan CA; Pirazzoli V; Wang L; Lu P; Vuong H; Hutchinson KE; Jia P; Chen X; Eisenberg R; Ladanyi M; Politi K; Zhao Z; Lovly CM; Cross DA; Pao W
Mol Cancer Ther; 2015 Feb; 14(2):542-52. PubMed ID: 25477325
[TBL] [Abstract][Full Text] [Related]
26. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
[TBL] [Abstract][Full Text] [Related]
27. CXCL12-regulated miR-370-3p functions as a tumor suppressor gene by targeting HMGA2 in nonfunctional pituitary adenomas.
Cai F; Dai C; Chen S; Wu Q; Liu X; Hong Y; Wang Z; Li L; Yan W; Wang R; Zhang J
Mol Cell Endocrinol; 2019 May; 488():25-35. PubMed ID: 30853598
[TBL] [Abstract][Full Text] [Related]
28. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
29. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
30. Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.
Dénes J; Kasuki L; Trivellin G; Colli LM; Takiya CM; Stiles CE; Barry S; de Castro M; Gadelha MR; Korbonits M
PLoS One; 2015; 10(2):e0117107. PubMed ID: 25658813
[TBL] [Abstract][Full Text] [Related]
31. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.
Butz H; Likó I; Czirják S; Igaz P; Khan MM; Zivkovic V; Bálint K; Korbonits M; Rácz K; Patócs A
J Clin Endocrinol Metab; 2010 Oct; 95(10):E181-91. PubMed ID: 20668041
[TBL] [Abstract][Full Text] [Related]
33. LncRNA SNHG7 sponges miR-449a to promote pituitary adenomas progression.
Yue X; Dong C; Ye Z; Zhu L; Zhang X; Wang X; Mo F; Li Z; Pan B
Metab Brain Dis; 2021 Jan; 36(1):123-132. PubMed ID: 32880813
[TBL] [Abstract][Full Text] [Related]
34. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
[TBL] [Abstract][Full Text] [Related]
35. MiR-130a-3p Inhibits PRL Expression and Is Associated With Heat Stress-Induced PRL Reduction.
Zhang H; Chen T; Xiong J; Hu B; Luo J; Xi Q; Jiang Q; Sun J; Zhang Y
Front Endocrinol (Lausanne); 2020; 11():92. PubMed ID: 32194503
[TBL] [Abstract][Full Text] [Related]
36. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.
Zhang Z; Zhang M; Liu H; Yin W
J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802
[TBL] [Abstract][Full Text] [Related]
37. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
Yoshida D; Koketshu K; Nomura R; Teramoto A
J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
[TBL] [Abstract][Full Text] [Related]
38. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.
Zhang R; Yang F; Fan H; Wang H; Wang Q; Yang J; Song T
Cell Death Dis; 2021 May; 12(6):524. PubMed ID: 34021124
[TBL] [Abstract][Full Text] [Related]
40. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
